Clinical trial
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
NCT00105092 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00105092 |
|---|---|
| Title | Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer. |
| Official title | A Phase II Evaluation of Oral Enzastaurin HCl in Second-and Third- Line Treatment of Patients With Non-Small Cell Lung Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | Enzastaurin HCL |
| Enrollment | 50 |
| Start date | Mar 1, 2005 |
| Completion | Feb 1, 2007 |
| First posted | Mar 7, 2005 |
| Last update posted | May 1, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: